NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Semdor Pharma Group

Semdor Pharma Group

Private
CologneHealthcare & Life Scienceshttps://semdor-group.com/

Last Round

Corporate Funding

Jan 15, 2021

Total Funding Raised

$48.3M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Semdor Pharma Group is a pharmaceutical company that specializes in narcotics and medical cannabis. Formed through the combination of Cannamedical Pharma GmbH and PS Pharma Group, the company provides a broad range of services including the import, handling, packaging, and distribution of narcotic medicines and medical cannabis products to wholesalers, suppliers, and pharmacies across Europe.

Sector

Healthcare & Life Sciences

Verticals

Pharma Supply Chain, Biotechnology, Telemedicine, Logistics Software

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Subscription SaaS

AI Layer

Application

Keywords

medical marijuananarcotics distributionmedical cannabiscontrolled substancespharma supply chainpharmaceutical logisticspharmaceutical manufacturingpain therapytelemedicine platformonline pharmacymail-order pharmacymedcanGMP certifiedGDP certified

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Semdor Pharma Group Comparables

Compare Semdor Pharma Group with similar companies based on industry and business-model similarity.

Semdor Pharma Group comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
SOMAÍ Pharmaceuticals
83%
Cansativa Group
81%
DEMECAN
79%

Semdor Pharma Group Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingJan 15, 2021

Key People

Founding team and executive leadership

David Henn

CEO

Executive Team

Justus Lassnig

Chief Operating Officer

Executive Team

Semdor Pharma Group Investors

Notable investors and investment history

Semdor Pharma Group investors
InvestorRounds
Orkila CapitalCorporate Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 20, 95% of headcount.

  • Jul 6, 2026

    Open roles increased from 0 to 4, representing 22% of headcount.

Semdor Pharma Group Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Semdor Pharma Group Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Semdor Pharma Group's valuation, stock price, and market status.

Firmographic Details

HeadquartersCologne
Employee Range21
Year Founded2021
Last FundingJan 15, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.